IP Verse

Tablet Including 7-[4-(4-Benzo[Beta]Thiophen-4-Yl-Piperazin-1-Yl) Butoxy]-1H-Quinolin-2-One Or Salt Thereof - EP2767285

The patent EP2767285 was granted to Otsuka Pharmaceutical on Feb 19, 2025. The application was originally filed on Oct 12, 2012 under application number EP12840025A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2767285

OTSUKA PHARMACEUTICAL
Application Number
EP12840025A
Filing Date
Oct 12, 2012
Status
Patent Maintained As Amended
Jan 17, 2025
Grant Date
Feb 19, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSAug 12, 2020ELKINGTON AND FIFEADMISSIBLE
MAIWALDAug 11, 2020MAIWALDADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONJP2006316052
EXAMINATIONUS2009318560
EXAMINATIONUS2010105710
INTERNATIONAL-SEARCH-REPORTJP2006316052
INTERNATIONAL-SEARCH-REPORTJP2008115172
OPPOSITIONEP2359816
OPPOSITIONUS2009318560
OPPOSITIONUS2010105710
OPPOSITIONUS2011152286
OPPOSITIONWO2006097344
OPPOSITIONWO2006112464
OPPOSITIONWO2012137971
SEARCHUS2011152286
SEARCHWO2012137971

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Otsuka HD Places Top Priority on Development of OPC-34712", Pharma Japan, (20110103), page 3, XP055426920
OPPOSITION- Anonymous, "Physicians' Desk Reference®", PDR® 61 EDITION, (20070000), page 882, XP055726449
OPPOSITION- "Brexpiprazole", Wikipedia - The free Encyclopedia, (20120311), pages 1 - 6, URL: https://en.wikipedia.org/w/index.php?title=Brexpiprazole&oldid= 481392710, XP055426855
OPPOSITION- "Chapter 13 - Tablet Dosage Forms", Florence Alexander T., Siepmann Juergen, Modern Pharmaceutics vol. 1 , Basic Principles and Systems, fifth edition, New York and London, vol. 1, pages 481 - 497, XP055752956
OPPOSITION- "''Coloring Agents'', ''Croscarmellose Sodium'', ''Hydroxypropyl Cellulose'', ''Hydroxypropyl Cellulose-Low-substituted'' and ''Sodium Starch Glycolate", Rowe, Raymond C., Paul J. Sheskey , Walter G. Cook , Marian E. Fenton, Handbook of Pharmaceutical Excipients sixth edition, London, (20090000), pages 317-323,189- 208 - 663-666, XP055752942
OPPOSITION- "Pharmaceutical Dosage Forms: Tablets", Paul W. S. Heng, Celine V. Liew, Pharmaceutical Dosage Forms: Tablets Third Edition, vol. 2: Rational Design and Formulation, New York and London, (20080000), vol. 2, pages 269 - 292, XP055752972
OPPOSITION- R.C. ROWE, "Synthetic irons oxides - the ideal pharaceutical colourants", Pharmacy International, (19840000), vol. 5, no. 9, pages 221 - 224, XP055726460
OPPOSITION- R.C. ROWE, "The opacity of tablet film coatings", Journal of Pharmacy and Pharmacology, (19840000), vol. 36, pages 569 - 572, XP003023689
OPPOSITION- "Tablet Formulation", James Swarbrick Et Al, Encyclopedia of Pharmaceutical Technology Third Edition volume 1, New York and London, (20070000), vol. 1, pages 3641 - 3672, XP055752951
OPPOSITION- S K Joneja , W W Harcum, G W Skinner, P E Barnum, J H Guo, "Investigating the Fundamental Effects of Binders on Pharmaceutical Tablet Performance", Drug Development and Industrial Pharmacy, (19990000), vol. 25, no. 10, pages 1129 - 1135, XP055752959
OTHER- "HIGHLIGHTS OF PRESCRIBING INFORMATION OF ABILIFY", OTSUKA PHARMACEUTICAL CO, (201102), pages 1 - 72, XP055217104
OTHER- KENJI MAEDA ET AL, "BREXPIPRAZOLE I: IN VITRO AND IN VIVO CHARACTERIZATION OF A NOVEL SEROTONIN-DOPAMINE ACTIVITY MODULATOR", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (20140619), vol. 350, no. 3, doi:10.1124/JPET.114.213793, pages 589 - 604, XP055217100
SEARCH- ROWE R C, "The Opacity of tablet film coatings", JOURNAL OF PHARMACY AND PHARMACOLOGY, JOHN WILEY & SONS LTD, LONDON; GB, (19840101), vol. 36, ISSN 0022-3573, pages 569 - 572, XP003023689 [Y] 7,11 * page 570 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents